Central retinal vein occlusion in a patient on hemodialysis secondary to antiphospholipid syndrome: Case report

Jabrane, Marouane; Ez-Zahraoui, Med Reda; Hajji, I; Fadili, W.; Moutaouakil, A.; Laouad, I.

doi:10.1016/j.nephro.2016.07.455

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12,23 Venous tortuosity was the most common posterior involvement. 22,26,27,32 APS has also been associated with central retinal vein occlusion, 7,23,27,32–46 branch retinal vein occlusion,, 24,25,34,37,41,45,47–51 central retinal artery occlusion and branch retinal artery occlusion, 37,43,52–58 or the coexistence of both arterial and venous bed thromboses in the same patient. 32,36,59–64 Venous stasis retinopathy, 65,66 vitreous 67,68 and intraretinal hemorrhages, 67 retinal vasculitis, 69,70 cotton wool spots, 67,71 neovascularization, 72 diffuse retinal periphlebitis, …”

Section: Part II – Systematic Review Of Ophthalmological Manifestatiomentioning

confidence: 99%

Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature

Franco

Medina

Balbi

et al. 2020

Lupus

View full text Add to dashboard Cite

Objective There is a broad spectrum of eye involvement in antiphospholipid syndrome (APS). The majority of descriptions are presented as case reports that include mostly APS patients secondary to systemic lupus erythematosus (SLE), with no compelling evidence in primary APS (PAPS). This study aimed to describe ocular manifestations in our well-defined PAPS cohort (APS-Rio) and then perform a systematic literature review (SLR) of ocular manifestations in patients with APS or positivity to aPL without SLE. Methods We retrospectively analyzed PAPS patients followed at our outpatient clinics. All patients fulfilled Sydney APS classification criteria (2006). We evaluated them for ocular symptoms and previous ocular diagnoses. Antiphospholipid antibodies and clinical APS manifestations were compared between patients with and without ocular manifestations. For the SLR, electronic databases were searched up to November 2019. Results We studied 105 PAPS patients; 90.5% were female and 56.2% were Caucasian. We found ocular manifestations in 37.1% of our cohort. Thrombosis was the main criteria manifestation (95.2%) and lupus anticoagulant was the most prevalent antibody. Ophthalmologic diagnoses were present in 7 patients, with 5 having retinal vessels thromboses. Amaurosis fugax was the leading complaint, present in 30 patients. In the univariate analysis, amaurosis fugax was related to livedo (p = 0.005), Raynaud’s phenomenon (p = 0.048) and the presence of anticardiolipin antibody (≥40 GPL/MPL) (p = 0.041). Hemianopia was associated with arterial hypertension (p = 0.049). In the multivariate analysis, the only association found was between livedo and amaurosis fugax (OR 4.09, 95%CI 1.5–11.11, p = 0.006). Our SLR incorporated 96 articles of ocular manifestations in patients with PAPS or positivity to aPL without SLE. Ocular findings varied from 5 to 88%, including anterior and posterior segments, orbital and neuro-ophthalmologic changes. Conclusion There is little evidence on ocular manifestations in PAPS. We described an association between livedo and amaurosis fugax. Prospective studies are needed to promote the best treatment and avoid blindness in PAPS patients.

show abstract

Section: Part II – Systematic Review Of Ophthalmological Manifestatiomentioning

confidence: 99%

Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature

Franco

Medina

Balbi

et al. 2020

Lupus

View full text Add to dashboard Cite

show abstract

“…Traditional medications that have been implemented for the treatment of primary APS include anticoagulant therapy. More recently, anti-vascular endothelial growth factor (VEGF) therapies have been introduced as an acceptable alternative to alleviate ocular symptoms [7] . Since various factors are involved in its pathogenesis, among which inflammation plays an important role, we believe that Ozurdex, an approved dexamethasone intravitreal implant, might be more effective in alleviating macular edema and improving visual acuity based on its anti-inflammatory mechanism, which is key in initiating procoagulant activity [8] .…”

Section: Dear Editormentioning

confidence: 99%

Combined central retinal artery and vein occlusion associated with primary antiphospholipid syndrome treated by injection of dexamethasone intravitreal implant and anticoagulant therapy: a case report

Lu¹,

Hao²,

Zhang³

et al. 2022

Int J Ophthalmol

View full text Add to dashboard Cite

“…opisali także przypadek wystąpienia obustronnego zawału naczyniówki u młodego mężczyzny z pierwotnym APS (6). W literaturze medycznej od wielu lat opisywane są przypadki incydentów zakrzepowo-zatorowych naczyń siatkówki ze współistnieniem przeciwciał antyfosfolipidowych, ze wskazaniem na to, że w okluzji naczyń siatkówki o niewyjaśnionym pochodzeniu przeciwciała antyfosfolipidowe mogą odgrywać istotną rolę w patogenezie (7)(8)(9)(10)(11). Stwierdzenie istnienia tej korelacji jest także o tyle ważne w diagnostyce, że objawy ze strony narządu wzroku mogą stanowić pierwszą manifestację kliniczną APS, wyprzedzając inne, bardziej typowe, a potencjalnie zagrażające życiu objawy.…”

Section: Omówienieunclassified

Ophthalmological manifestations in antiphospholid syndrome – case series

Ostrowska-Spaleniak¹,

Krix-Jachym²,

Rękas³

2019

View full text Add to dashboard Cite

Zespół antyfosfolipidowy (inaczej zespół Hughesa, ang. Antiphospholipid Syndrome-APS) jest autoimmunologiczną chorobą, która charakteryzuje się zakrzepicą żylną i/lub tętniczą, niepowodzeniami położniczymi oraz występowaniem w surowicy prozakrzepowych przeciwciał antyfosfolipidowych (ang. Antiphospholipid Antibodies-aPLA): antykoagulantu toczniowego (ang. Lupus Anticoagulant-LA), przeciwciał antykardiolipinowych (ang. Anticardiolipin Antibodies-aCL) i przeciwciał przeciwko β2-glikoproteinie I (anti-β2-glycoprotein I antibodies-aβ2-GPI). Wyróżnia się APS pierwotny-niezwiązany z innymi chorobami-oraz wtórny do chorób tkanki łącznej-najczęściej współwystępuje z toczniem rumieniowatym układowym (ang. Systemic Lupus Erythematosus-SLE) w 30-50% przypadków. W przebiegu APS może dojść do zajęcia naczyń tętniczych, żylnych i włosowatych we wszystkich narządach i tkankach, z tym jest związana bogata symptomatologia zespołu. Dominującym objawem jest zakrzepica żył głębokich kończyn dolnych, powikłana w połowie przypadków zatorowością płucną. Ostre lub przewlekłe stany niedokrwienne spowodowane zakrzepami

show abstract

Central retinal vein occlusion in a patient on hemodialysis secondary to antiphospholipid syndrome: Case report

Cited by 4 publications

References 19 publications

Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature

Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature

Combined central retinal artery and vein occlusion associated with primary antiphospholipid syndrome treated by injection of dexamethasone intravitreal implant and anticoagulant therapy: a case report

Ophthalmological manifestations in antiphospholid syndrome – case series

Contact Info

Product

Resources

About